CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE

Clinical trials for CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE explained in plain language.

Never miss a new study

Get alerted when new CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE trials appear

Sign up with your email to follow new studies for CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for transplant patients whose bodies fight back

Disease control Recruiting now

This study is testing the drug ruxolitinib in Chinese adults and adolescents (aged 12+) who have chronic graft-versus-host disease (cGvHD) that does not improve with standard steroid treatment. The goal is to see if ruxolitinib can help control the disease and reduce symptoms. Ab…

Matched conditions: CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE

Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Apr 01, 2026 14:43 UTC

CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE

Get alerted when new CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE trials appear

New hope for transplant patients whose bodies fight back